Literature DB >> 21533991

Effects of the dopamine stabilizers (S)-(-)-OSU6162 and ACR16 on prolactin secretion in drug-naive and monoamine-depleted rats.

Johan P Rung1, Emilia Rung, Anette M Johansson, Kjell Svensson, Arvid Carlsson, Maria L Carlsson.   

Abstract

Dopaminergic stabilizers may be conceptualized as drugs with normalizing effects on dopamine-mediated behaviours and neurochemical events. (S)-(-)-OSU6162 (OSU6162) and ACR16 are two structurally related compounds ascribed such properties, principally because of their stabilizing effects on motor activity in rodents. Reports in the literature indicate possible partial D2 receptor agonist effects using various in vitro systems. This study aimed to measure D2 receptor antagonist and agonist effects of OSU6162 and ACR16 in vivo. To address this, we have studied the effects of both compounds on prolactin secretion in drug-naive and dopamine-depleted rats; dopamine depletion was induced by pretreatment with reserpine plus α-methyl-DL: -p-tyrosine. We find that OSU6162 and ACR16 both stimulate prolactin secretion in drug-naive rats with OSU6162 being considerably more potent and efficacious. Both compounds show a non-significant trend towards reversal of the increased secretion caused by dopamine depletion, whereas the D2 receptor antagonist haloperidol further increased prolactin secretion. Thus, this study suggests that OSU6162 and ACR16 act as D2 receptor antagonists under normal conditions in vivo, possibly with minor agonist effects in a state of dopamine depletion.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21533991     DOI: 10.1007/s00210-011-0641-y

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  18 in total

1.  Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's disease.

Authors:  Anders Lundin; Espen Dietrichs; Sara Haghighi; Marie-Louise Göller; Arvid Heiberg; Ghada Loutfi; Håkan Widner; Klas Wiktorin; Leif Wiklund; Anders Svenningsson; Clas Sonesson; Nicholas Waters; Susanna Waters; Joakim Tedroff
Journal:  Clin Neuropharmacol       Date:  2010 Sep-Oct       Impact factor: 1.592

2.  Effects of (-)-OSU6162 and ACR16 on motor activity in rats, indicating a unique mechanism of dopaminergic stabilization.

Authors:  Johan P Rung; Emilia Rung; Lisa Helgeson; Anette M Johansson; Kjell Svensson; Arvid Carlsson; Maria L Carlsson
Journal:  J Neural Transm (Vienna)       Date:  2008-03-20       Impact factor: 3.575

3.  Long-lasting improvement following (-)-OSU6162 in a patient with Huntington's disease.

Authors:  J Tedroff; A Ekesbo; C Sonesson; N Waters; A Carlsson
Journal:  Neurology       Date:  1999-10-22       Impact factor: 9.910

Review 4.  Sexuality and schizophrenia: a review.

Authors:  Deanna L Kelly; Robert R Conley
Journal:  Schizophr Bull       Date:  2004       Impact factor: 9.306

5.  Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties.

Authors:  Martyn D Wood; Claire Scott; Kirsten Clarke; Julie Westaway; Ceri H Davies; Charlie Reavill; Mark Hill; Claire Rourke; Michael Newson; Declan N C Jones; Ian T Forbes; Andrew Gribble
Journal:  Eur J Pharmacol       Date:  2006-07-21       Impact factor: 4.432

6.  Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine(preclamol) in schizophrenia.

Authors:  A C Lahti; M A Weiler; P K Corey; R A Lahti; A Carlsson; C A Tamminga
Journal:  Biol Psychiatry       Date:  1998-01-01       Impact factor: 13.382

7.  Dopamine partial agonist action of (-)OSU6162 is consistent with dopamine hyperactivity in psychosis.

Authors:  Philip Seeman; Hong-Chang Guan
Journal:  Eur J Pharmacol       Date:  2006-11-14       Impact factor: 4.432

8.  Analysis of the actions of the novel dopamine receptor-directed compounds (S)-OSU6162 and ACR16 at the D2 dopamine receptor.

Authors:  Elodie Kara; Hong Lin; Kjell Svensson; Anette M Johansson; Philip G Strange
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

9.  The dopaminergic stabilizers (-)-OSU6162 and ACR16 reverse (+)-MK-801-induced social withdrawal in rats.

Authors:  Johan P Rung; Arvid Carlsson; Katarina Rydén Markinhuhta; Maria L Carlsson
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2005-06       Impact factor: 5.067

10.  The dopaminergic stabilizers pridopidine (ACR16) and (-)-OSU6162 display dopamine D(2) receptor antagonism and fast receptor dissociation properties.

Authors:  Tino Dyhring; Elsebet Ø Nielsen; Clas Sonesson; Fredrik Pettersson; Jonas Karlsson; Peder Svensson; Palle Christophersen; Nicholas Waters
Journal:  Eur J Pharmacol       Date:  2009-11-15       Impact factor: 4.432

View more
  4 in total

1.  I. In vivo evidence for partial agonist effects of (-)-OSU6162 and (+)-OSU6162 on 5-HT2A serotonin receptors.

Authors:  Maria L Carlsson; Ethan S Burstein; Angélica Kloberg; Sarah Hansson; Arja Schedwin; Marie Nilsson; Johan P Rung; Arvid Carlsson
Journal:  J Neural Transm (Vienna)       Date:  2011-08-28       Impact factor: 3.575

2.  The dopamine stabilizer (-)-OSU6162 occupies a subpopulation of striatal dopamine D2/D3 receptors: an [(11)C]raclopride PET study in healthy human subjects.

Authors:  Nelleke Tolboom; Henk W Berendse; Josee E Leysen; Maqsood Yaqub; Bart N M van Berckel; Robert C Schuit; Mirthe M Ponsen; Esther Bakker; Nikie J Hoetjes; Albert D Windhorst; Maria L Carlsson; Adriaan A Lammertsma; Arvid Carlsson
Journal:  Neuropsychopharmacology       Date:  2014-08-05       Impact factor: 7.853

3.  The effects of the dopamine stabilizer (-)-OSU6162 on aggressive and sexual behavior in rodents.

Authors:  E Studer; J Näslund; A Westman; A Carlsson; E Eriksson
Journal:  Transl Psychiatry       Date:  2016-03-22       Impact factor: 6.222

Review 4.  Pridopidine: Overview of Pharmacology and Rationale for its Use in Huntington's Disease.

Authors:  Susanna Waters; Joakim Tedroff; Henrik Ponten; Daniel Klamer; Clas Sonesson; Nicholas Waters
Journal:  J Huntingtons Dis       Date:  2018
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.